HMGA2 and acute myeloid leukemia: We next studied whether the HMGA2 test could improve prognostic assessment in AML patients classified according to the 2017 ELN genetic risk stratification.1 We found that 45 out of 87 ELN adverse-risk patients (51.7%) (Table 1, Supplementary Table S14) were positive for the HMGA2 test and had a significantly worse survival (Supplementary Figure S9, right panel, red curve).